In particular, in patients treated with nab-paclitaxel plus gemcitabine (27 in 39 patients) Cav-1 expression was associated with significantly worse OS (HR = 5.01, 95%CI: 1.85–13.52, p = 0.0015)...high Cav-1 expression was associated with significantly worse OS both in patients with locally advanced disease (median OS: 7.15 vs. 16.82 months, HR:8.26, 95% CI: 2.16–31.45, p = 0.002) and in metastatic patients (median OS: 5.18 vs. 22.33 months, HR:4.24, 95%CI:1.45–12.33, p = 0.008). PFS was also significantly shorter in locally advanced patients with high Cav-1 expression compared to patients with low expression (4.72 vs. 7.87 months, HR:3.85, 95%CI:1.18–12.54, p = 0.002).